Eudratec Fasteric is an oral drug delivery technology that offers enteric protection after rapid, homogeneous release for targeting the upper small intestine.
Evonik announced on Oct. 6, 2020 that it has launched Eudratec Fasteric, an oral drug delivery technology that offers enteric protection after rapid, homogeneous release for targeting the upper small intestine.
The new technology can release 90% of its dose within 30 minutes of arrival at a pre-defined pH level between 3.0 and 5.5, while increasing gastric resistance and improving intestinal absorption for oral drug products, a company press release said. The technology can be used with standard equipment and a range of oral dosage forms including multiparticulates, tablets, and capsules.
“Many APIs are best absorbed through the proximal part of the small intestine,” said Paul Spencer, head of Pharma Polymers and Services at Evonik, in the press release. “Enteric protection, followed by early, fast, and homogeneous release at the right pH level, can be essential to maximize absorption and enhance bioavailability. With the launch of Eudratec Fasteric, Evonik has addressed another major unmet need for oral drug delivery.”
Source: Evonik
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.